Integrated Drug Discovery Programs at ChemPartner

End-to-End Solutions from Target to IND and Beyond – Small Molecule & Large Molecule Modalities

One Coordinated Team from Early Discovery to Development Readiness

ChemPartner’s Integrated Programs bring together the scientific disciplines required to move therapeutic candidates from early discovery through development readiness. Across both small molecule and biologic modalities, our teams connect medicinal chemistry, antibody discovery, protein science, biology, DMPK, exploratory toxicology, formulation development, CMC, and manufacturing support within a coordinated operating model.

Whether a program begins with target validation, hit identification, antibody generation, lead optimization, or candidate selection, ChemPartner provides flexible engagement models – including FTE, FFS, and blended teams – to help sponsors advance programs efficiently across key decision points and development milestones.

ChemPartner delivers discovery, development, and manufacturing across a global infrastructure supporting standalone projects and integrated programs.

medicinal and synthetic chemists

700+

ChemPartner supports:

Extensive biologics discovery and antibody engineering capabilities

GMP manufacturing capabilities for biologic drug substance and drug product

Dedicated DMPK, bioanalysis, and exploratory toxicology teams

Flexible FTE, FFS, and blended engagement models

Stable cell line development and biologics CMC expertise

Experience supporting programs from discovery through regulatory milestones

From Discovery Strategy to Development Readiness

Drug discovery rarely follows a linear path. Progress depends on the ability to connect adjacent scientific functions, rapidly generate data, and make informed development decisions.

ChemPartner’s integrated model combines discovery chemistry, biologics discovery, in vitro and in vivo pharmacology, ADME, pharmacokinetics, bioanalysis, exploratory toxicology, formulation development, and CMC support within a coordinated framework.

By reducing operational handoffs and aligning multidisciplinary teams around program objectives, sponsors can move more efficiently from early research through IND-enabling activities.

Two Pathways, Small Molecules and Biologics, One Integrated Platform

Advancing Small Molecule Programs from Discovery to IND

ChemPartner’s Small Molecule Discovery to IND pathway connects medicinal chemistry, discovery biology, DMPK, bioanalysis, exploratory toxicology, formulation development, and CMC support across the drug discovery lifecycle.

From hit identification and hit-to-lead optimization through candidate selection and IND-enabling studies, integrated teams provide the expertise and continuity needed to advance small molecule programs efficiently toward development milestones.

Key capabilities include

Large Molecule Discovery to CMC and GMP Manufacturing

Support biologics programs from discovery through development and manufacturing with integrated biologics discovery, antibody engineering, protein science, ADC/XDC capabilities, stable cell line development, CMC, and GMP manufacturing.

Key capabilities include

Frequently asked questions

What is included in Small Molecule Discovery to IND?

ChemPartner’s Small Molecule Discovery to IND pathway spans medicinal chemistry, assay development, hit identification, hit-to-lead optimization, lead optimization, DMPK, bioanalysis, exploratory toxicology, formulation development, CMC support, and IND-enabling activities. The program is designed to support progression from early discovery through development readiness.

What does Large Molecule End-to-End CRO/CDMO Solutions include?

The Large Molecule pathway covers protein science, antibody discovery, antibody engineering, multispecific antibody development, ADC/XDC development, stable cell line development, process development, formulation development, biologics CMC, and GMP manufacturing support from discovery through development.

Can small molecule and biological programs share supporting capabilities?

Yes. Both pathways leverage shared capabilities including biology, pharmacology, assay development, DMPK, bioanalysis, translational models, formulation development, and AI-enabled discovery. These cross-functional capabilities help support multidisciplinary programs and emerging therapeutic modalities.

How does ChemPartner help move programs from discovery to development?

ChemPartner connects discovery chemistry, biologics discovery, pharmacology, DMPK, exploratory toxicology, formulation, CMC, and manufacturing expertise within a coordinated development framework. This integrated approach helps reduce handoffs, improve decision-making, and support progression toward IND and clinical milestones.

Does ChemPartner support integrated small molecule programs or individual services?

ChemPartner supports both fully integrated drug discovery programs and standalone service engagements. Clients can work through flexible FTE, fee-for-service (FFS), or blended team models depending on project goals, timelines, and resource requirements.

Does ChemPartner support ADC and other conjugated biologic modalities?

Yes. ChemPartner supports antibody-drug conjugates (ADCs), multispecific antibodies, protein engineering, linker-payload development, conjugation workflows, and in vitro and in vivo characterization. The platform also supports emerging biologic and targeted therapeutic modalities.

Where do biologics CMC and GMP manufacturing fit within the development pathway?

Biologics CMC, process development, formulation development, stable cell line development, and GMP manufacturing are part of the Large Molecule End-to-End CRO/CDMO Solutions pathway. These capabilities provide continuity from antibody discovery and candidate selection through clinical and commercial manufacturing support.

Explore the right path for your program

Whether your organization is advancing a small molecule therapeutic, monoclonal antibody, ADC, multispecific antibody, peptide, oligonucleotide, or other emerging modality, ChemPartner can provide the scientific expertise and operational continuity needed to support each stage of development.

Talk to Our Team About an Integrated Program

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Explore Small Molecule Discovery to IND

Lorem ipsum dolor sit amet consectetur. Nisl commodo integer egestas sit ut. Platea eget risus velit risus in molestie.

Explore Large Molecule End-to-End CRO/CDMO Solutions

Lorem ipsum dolor sit amet consectetur. Nisl commodo integer egestas sit ut. Platea eget risus velit risus in molestie.